Gene expression-based risk score in diffuse large B-cell lymphoma.

Abstract : Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma and displays heterogeneous clinical and molecular characteristics. In this study, high throughput gene expression profiling of DLBCL tumor samples was used to design a 12-gene expression-based risk score (GERS) predictive for patient's overall survival. GERS allowed identifying a high-risk group comprising 46,4% of the DLBCL patients in two independent cohorts (n=414 and n=69). GERS was shown to be an independent predictor of survival when compared to the previously published prognostic factors, including the International Prognostic Index (IPI). GERS displayed a prognostic value in germinal-center B-cell-like subgroup (GCB) and activated B cell-like (ABC) molecular subgroups of patients as well as in DLBCL patients treated with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) or Rituximab-CHOP (R-CHOP) regimens. Combination of GERS and IPI lead to a potent prognostic classification of DLBCL patients. Finally, a genomic instability gene signature was highlighted in gene expression profiles of patients belonging to the high-risk GERS-defined group.
Type de document :
Article dans une revue
Oncotarget, Impact journals, 2012, 3 (12), pp.1700-10
Liste complète des métadonnées
Contributeur : Monique Frei <>
Soumis le : mercredi 20 mars 2013 - 10:13:34
Dernière modification le : mardi 11 septembre 2018 - 10:16:02
Document(s) archivé(s) le : vendredi 21 juin 2013 - 04:12:45


Fichiers éditeurs autorisés sur une archive ouverte


  • HAL Id : inserm-00802570, version 1
  • PUBMED : 23482333



Caroline Bret, Bernard Klein, Jérôme Moreaux. Gene expression-based risk score in diffuse large B-cell lymphoma.. Oncotarget, Impact journals, 2012, 3 (12), pp.1700-10. 〈inserm-00802570〉



Consultations de la notice


Téléchargements de fichiers